PT2776065T - Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas - Google Patents

Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas

Info

Publication number
PT2776065T
PT2776065T PT128474798T PT12847479T PT2776065T PT 2776065 T PT2776065 T PT 2776065T PT 128474798 T PT128474798 T PT 128474798T PT 12847479 T PT12847479 T PT 12847479T PT 2776065 T PT2776065 T PT 2776065T
Authority
PT
Portugal
Prior art keywords
binding molecules
combination therapies
pseudomonas psl
pcrv binding
pcrv
Prior art date
Application number
PT128474798T
Other languages
English (en)
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PT2776065T publication Critical patent/PT2776065T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT128474798T 2011-11-07 2012-11-06 Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas PT2776065T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556645P 2011-11-07 2011-11-07
US201261625299P 2012-04-17 2012-04-17
US201261697585P 2012-09-06 2012-09-06

Publications (1)

Publication Number Publication Date
PT2776065T true PT2776065T (pt) 2020-09-25

Family

ID=48290482

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128474798T PT2776065T (pt) 2011-11-07 2012-11-06 Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas

Country Status (22)

Country Link
US (3) US10597439B2 (pt)
EP (1) EP2776065B1 (pt)
JP (1) JP6182152B2 (pt)
KR (1) KR102184343B1 (pt)
CN (1) CN104136042B (pt)
AU (3) AU2012336028A1 (pt)
BR (1) BR112014011028B1 (pt)
CA (2) CA2854817C (pt)
CY (1) CY1123552T1 (pt)
DK (1) DK2776065T3 (pt)
ES (1) ES2859323T3 (pt)
HK (1) HK1201453A1 (pt)
HR (1) HRP20201370T1 (pt)
HU (1) HUE050985T2 (pt)
LT (1) LT2776065T (pt)
MX (1) MX2014005566A (pt)
PL (1) PL2776065T3 (pt)
PT (1) PT2776065T (pt)
RS (1) RS60920B1 (pt)
RU (1) RU2687588C2 (pt)
SI (1) SI2776065T1 (pt)
WO (1) WO2013070615A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
CA2854817C (en) 2011-11-07 2022-08-16 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
SG11201404532XA (en) * 2012-03-02 2014-08-28 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
WO2014186358A2 (en) * 2013-05-14 2014-11-20 Antonio Digiandomenico Synthetic oligosaccharide subunits of the psl exoplysaccharide of pseudomonas aeruginosa and uses therof
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
KR20180020142A (ko) 2015-05-01 2018-02-27 인히브릭스 엘피 Iii형 분비계 표적화 분자
AU2016313653A1 (en) * 2015-08-24 2018-04-12 Medimmune, Llc MrkA polypeptides, antibodies, and uses thereof
EP3383884A4 (en) * 2015-11-30 2019-07-31 Medimmune Limited PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA
KR20230093338A (ko) * 2016-05-05 2023-06-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
MX2021015156A (es) 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
BR112021026788A2 (pt) * 2019-07-09 2022-05-10 Staidson Beijing Biopharmaceuticals Co Ltd Anticorpos que reconhecem especificamente pcrv de pseudomonas e usos dos mesmos
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
EP4192856A1 (en) * 2020-08-07 2023-06-14 Beijing SoloBio Genetechnology Company Ltd. Antibodies specifically recognizing pseudomonas psl and uses thereof
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
KR20230109703A (ko) * 2020-11-18 2023-07-20 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 슈도모나스 pcrv 및 psl을 특이적으로 식별하는 항체 결합을 포함하는 항체 조합 및 이중특이성 항체
WO2023141611A2 (en) * 2022-01-21 2023-07-27 Lyvgen Biopharma Holdings Limited Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
WO2024003103A1 (en) 2022-06-29 2024-01-04 Astrazeneca Ab Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0215131B1 (en) 1985-03-11 1992-06-17 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
ATE539349T1 (de) 1998-11-25 2012-01-15 Mcw Res Found Inc Verfahren zur diagnose einer pseudomonas aeruginosa infektion
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP3569610A3 (en) 2000-12-12 2020-03-18 Medlmmune, LLC Molecules with extended half lives, compositions and uses thereof
ATE347374T1 (de) 2001-01-26 2006-12-15 Mcw Res Found Inc Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
KR20100097719A (ko) 2007-11-30 2010-09-03 칼로바이오스 파마슈티컬스, 아이엔씨. 슈도모나스 아에루기노사의 ＰｃｒＶ 항원에 대한 항체
PT2248826E (pt) * 2008-01-10 2013-09-06 Shionogi & Co Anticorpo dirigido contra pcrv
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
NZ606283A (en) 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9061811B2 (en) * 2008-12-31 2015-06-23 Lothar Egersdoerfer Venting device
EP2393515A1 (en) * 2009-02-04 2011-12-14 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
ES2529734T7 (es) * 2009-03-11 2015-08-11 Shionogi & Co., Ltd. Anticuerpo PcrV humanizado con actividad anti-pseudomonas
EP2408475B1 (en) * 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
US20120114657A1 (en) 2009-04-09 2012-05-10 Kenta Biotech Ag Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011087799A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
WO2012145626A1 (en) 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CA2854817C (en) 2011-11-07 2022-08-16 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
SG11201404532XA (en) * 2012-03-02 2014-08-28 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
HUE049012T2 (hu) * 2012-11-06 2020-09-28 Medimmune Llc Antitestek S. aureus felszíni determinánsok ellen
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
MX367082B (es) * 2012-11-06 2019-08-05 Medimmune Llc Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.
WO2014186358A2 (en) 2013-05-14 2014-11-20 Antonio Digiandomenico Synthetic oligosaccharide subunits of the psl exoplysaccharide of pseudomonas aeruginosa and uses therof
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
EP3383884A4 (en) * 2015-11-30 2019-07-31 Medimmune Limited PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA
KR20230093338A (ko) * 2016-05-05 2023-06-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
MX2021015156A (es) * 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.

Also Published As

Publication number Publication date
PL2776065T3 (pl) 2020-12-14
LT2776065T (lt) 2020-10-12
RU2687588C2 (ru) 2019-05-15
NZ722379A (en) 2019-12-20
EP2776065A4 (en) 2016-03-02
SI2776065T1 (sl) 2020-10-30
WO2013070615A8 (en) 2013-06-20
US10597439B2 (en) 2020-03-24
MX2014005566A (es) 2014-10-14
NZ624072A (en) 2016-09-30
EP2776065B1 (en) 2020-08-05
CN104136042B (zh) 2017-08-18
CA3161431A1 (en) 2013-05-16
JP6182152B2 (ja) 2017-08-16
AU2012336028A1 (en) 2014-06-26
AU2019226205A1 (en) 2019-09-26
HUE050985T2 (hu) 2021-01-28
US20150023966A1 (en) 2015-01-22
AU2017219081B2 (en) 2019-06-06
KR102184343B1 (ko) 2020-11-30
US20220177554A1 (en) 2022-06-09
HRP20201370T1 (hr) 2020-11-27
WO2013070615A1 (en) 2013-05-16
CY1123552T1 (el) 2022-03-24
ES2859323T3 (es) 2021-10-01
KR20140091736A (ko) 2014-07-22
CA2854817C (en) 2022-08-16
AU2017219081B9 (en) 2019-07-04
CN104136042A (zh) 2014-11-05
AU2017219081A1 (en) 2017-09-14
BR112014011028B1 (pt) 2021-03-02
DK2776065T3 (da) 2020-10-12
CA2854817A1 (en) 2013-05-16
RU2014122990A (ru) 2015-12-20
US20200317757A1 (en) 2020-10-08
JP2015504421A (ja) 2015-02-12
BR112014011028A2 (pt) 2017-05-02
HK1201453A1 (en) 2015-09-04
RS60920B1 (sr) 2020-11-30
US11203633B2 (en) 2021-12-21
EP2776065A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
HK1201453A1 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules psl pcrv
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL288203A (en) Meditops and Meditop binding antibodies and their use
HK1257190A1 (zh) 抗假單胞菌psl結合分子及其用途
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
SG11201502937PA (en) COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES